Psyched: A $100M Donation Pledge, Frank Biden Gets Candid, New Search Trends & More
World's Largest Psychedelics Conference Boasts 12K Attendees
Psyched: $75M In Federal Funds, Gov. Polis Opens MAPS Event, CNN’s Show, Dock Ellis’ LSD Pitch & More
Federal Psychedelics: $75M Grant Program
Burning Man CEO Learned ‘So Much’ About Psychedelics In BRC: ‘We’re Here For The Love’
Burning Man CEO Marian Goddell attended Psychedelic Science 2023 in Denver, where she spoke with MAPS strategic initiatives officer Lia
Small Pharma Implements Cost-Cutting Strategy To Reduce Cash Burn As Trial Progresses
UK-based biotech firm Small Pharma Inc. (OTCQB: DMTTF) shared its financial outcomes for the fiscal year ended Feb. 28, plus pipeline updates.
Highlights:
Reunion Neuroscience’s Q4 And Full Year 2023 Financial Results, To Close Take-Private Deal In Q3
Clinical-stage psychedelics firm Reunion Neuroscience Inc. (NASDAQ: REUN) reported fiscal results for the fourth quarter and year ended March 31 plus corporate updates.
Here's a breakdown of the report:
This Biotech Is Entering The Clinical Stage With A Psilocin Analog Targeting Cluster Headaches
Lobe Sciences Ltd. (OTCQB: LOBEF), a biopharmaceutical company focused on non-hallucinatory doses of stabilized psychedelic-based compounds to treat rare diseases, has commenced its Phase 1 clinical study on proprietary psilocin analog L-130.
BetterLife Fast Tracks Its US Patent For Non-Hallucinogenic Compound And Other LSD Derivatives
Psychedelics biotech BetterLife Pharma Inc. (OTCQB: BETRF) is fast-tracking its U.S.
Cybin’s FY2023 Financials, Guidance And Appointment Of Sanford R. Climan As Strategic Advisor
Psychedelics biopharma company Cybin Inc. (NYSE: CYBN) shared its financial results for the fiscal year ended this March 31 as well as recent business highlights.
Numbers show:
Total cash of $12.5 (CA$16.6) million by March 31, 2023.
Ketamine News: PharmaTher Begins FDA Filing For KETARX Application, Stella Acquires Field Trip Assets
Specialty biotech company PharmaTher Holdings Ltd. (OTCQB: PHRRF) has filed a pre-submission facility correspondence in advance of its Abbreviated New Drug Application (ANDA) for its novel racemic ketamine KETARX to the FDA.
Exclusive: Search Trends Reveal America’s Fascination With Psychedelics And Cannabis
A shift is occurring in America's consciousness and search habits as the nation plunges headfirst into the psychedelics and cannabis revolution, an analysis by SEMRush (NYSE: SEMR) provided exclusively to Benzin